ArticleEuropean journal of breast health2025
Evaluation of Serum STARD3 Levels in Patients With Breast and Prostate Cancer: A Case-Control Study.
Article in European journal of breast health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Cancer cells exhibit high metabolic demands and rely heavily on lipid metabolism for proliferation and membrane synthesis. Lipid transfer proteins, particularly the steroidogenic acute regulatory-related lipid transfer domain 3 (STARD3), play a significant role in intracellular cholesterol transport and may influence cancer progression. The aim of this study was to investigate serum STARD3 levels in patients with breast and prostate cancer and compare them with healthy controls, along with lipid parameters. Materials and Methods: Patients with breast cancer (women) and prostate cancer (men) were recruited together with a control group matched by age-range and sex. Serum samples were collected, and STARD3 levels were measured using a commercial ELISA kit. Lipid parameters and tumor markers (carbohydrate antigen 15-3, prostate-specific antigen) were also evaluated. Results: A total of 200 individuals were enrolled: 50 female breast cancer patients, 50 male prostate cancer patients, and 100 healthy controls. STARD3 levels were significantly lower in both breast cancer ( Conclusion: The results suggest that STARD3 may play a role in the pathogenesis of both hormone-related cancers, although the mechanism remains unclear. Given the limited studies evaluating STARD3 in both breast and prostate cancers simultaneously, our findings contribute novel data to the literature and may guide future research into the diagnostic or prognostic potential of STARD3 in oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.